Triptorelin

A GnRH agonist approved for prostate cancer, endometriosis and central precocious puberty.

What research shows

Triptorelin is a licensed medicine with phase III oncology evidence, randomized dose-escalation research, and pooled paediatric data in central precocious puberty. It is a prescription hormonal agent with significant effects, not a wellness compound, and is included here for that contrast.

Evidence strength

Highest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.